Imipenem-cilastatin as initial therapy for febrile cancer patients.
Imipenem-cilastatin was used to treat 79 febrile episodes in 71 cancer patients, most of whom had neutropenia. The overall response rate was 67%, and 76% of the 45 documented infections responded. The response rates for septicemias and pneumonias were 79 and 62%, respectively. Only 1 of the 17 infec...
Saved in:
| Published in: | Antimicrob Agents Chemother |
|---|---|
| Main Authors: | , , , , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
American Society for Microbiology (ASM)
1986
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC180520/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/3532942/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/aac.30.2.211 |
| Tags: |
No Tags, Be the first to tag this record!
|